Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE AND ASPIRIN (HALF-STRENGTH) vs PATADAY ONCE DAILY RELIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, resulting in analgesia through supraspinal and spinal pathways. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin synthesis and providing anti-inflammatory and analgesic effects.
Olopatadine is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits release of histamine and other mediators from mast cells, reducing allergic conjunctivitis symptoms.
Moderate to moderately severe pain (when combination therapy is appropriate),Off-label: acute pain, chronic pain
Treatment of ocular itching associated with allergic conjunctivitis (FDA-approved)
Adults: One to two tablets (325 mg aspirin/2.5 mg oxycodone per tablet) orally every 6 hours as needed for pain. Maximum dose: 12 tablets per day.
1 drop in each affected eye once daily. The ophthalmic solution is 0.2% (olopatadine hydrochloride).
Aspirin: 2-3 hours for low doses, 15-30 hours for anti-inflammatory doses; increased half-life with dose due to saturable metabolism. Oxycodone: Immediate release: 3-4 hours; controlled release: 4.5-5 hours with biphasic absorption.
Terminal elimination half-life is approximately 9 hours; allows twice-daily dosing for sustained symptom control.
Oxycodone is extensively metabolized in the liver via CYP3A4 (N-demethylation to noroxycodone) and CYP2D6 (O-demethylation to oxymorphone). Aspirin is rapidly hydrolyzed to salicylic acid by esterases in the liver and plasma; salicylic acid is conjugated primarily with glycine (salicyluric acid) and glucuronic acid.
Olopatadine undergoes minimal hepatic metabolism; approximately 60-70% excreted unchanged in urine. Metabolites include N-demethylated and N-oxide derivatives; CYP450 enzymes not significantly involved.
Aspirin: Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylate); 10% excreted as unchanged salicylate. Oxycodone: Renal (primarily as noroxycodone, oxymorphone, and conjugates); approximately 87% eliminated in urine, 10-14% in feces.
Primarily renal excretion: approximately 60% of dose excreted unchanged in urine; fecal elimination accounts for less than 10%.
Aspirin: 80-90% (primarily to albumin, saturable). Oxycodone: 38-45% (primarily to albumin).
Approximately 70-80% bound to plasma proteins, primarily albumin.
Aspirin: 0.15-0.2 L/kg. Oxycodone: 2.0-3.7 L/kg; extensive tissue distribution.
Volume of distribution is approximately 1.4 L/kg, indicating distribution into total body water.
Oral: Aspirin: 80-100% (first-pass hydrolysis to salicylate). Oxycodone: 60-87% (oral); rectal: similar to oral; intravenous: 100%.
Ocular bioavailability is low due to nasolacrimal drainage and systemic absorption; systemic bioavailability from ocular dose is less than 5%.
For GFR 10-50 m L/min: Administer 75% of usual dose at extended intervals (every 8-12 hours). For GFR <10 m L/min: Avoid use due to risk of aspirin accumulation and oxycodone toxicity.
No dosage adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), use with caution as safety has not been established.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Initiate at 50-75% of usual dose and titrate cautiously. Child-Pugh Class C: Avoid use due to risk of oxycodone accumulation and aspirin-induced bleeding.
No dosage adjustment required for mild to moderate hepatic impairment. For severe hepatic impairment (Child-Pugh class C), use with caution as safety has not been established.
Not recommended for pediatric use due to risk of Reye's syndrome from aspirin and lack of safety data for oxycodone in children <18 years.
For children 2 years of age and older: 1 drop in each affected eye once daily. Safety and efficacy in children under 2 years have not been established.
Initiate at the low end of dosing range (e.g., one tablet every 6 hours) due to increased sensitivity to opioid effects and risk of aspirin-induced gastrointestinal bleeding. Titrate slowly and monitor renal function.
No specific dosage adjustment required. Use the same dose as for younger adults. Overall, no differences in safety or efficacy were observed between elderly and younger patients.
Addiction, abuse, and misuse risk; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; cytochrome P450 3A4 interaction with concomitant CNS depressants; risk of Reye syndrome (aspirin) in children and teenagers with viral illnesses.
None.
Respiratory depression; drug dependence, abuse, and addiction; CNS depression (additive with other CNS depressants); head injury and increased intracranial pressure; hypotension; seizure disorders; biliary tract disease; impaired renal or hepatic function; history of gastrointestinal bleeding (aspirin); bleeding disorders (aspirin); concurrent use with anticoagulants; Reye syndrome; hypersensitivity to aspirin or NSAIDs; pregnant women (prolonged use may cause neonatal withdrawal).
Not for injection; for topical ophthalmic use only.,Do not wear contact lenses if eyes are red; wait at least 10 minutes after instillation before inserting lenses.,Contains benzalkonium chloride which may be absorbed by soft contact lenses.,May cause transient stinging or burning upon instillation.
Hypersensitivity to oxycodone, aspirin, or any component; severe respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; Reye syndrome (in children/teenagers with viral illness) (aspirin); pregnancy (prolonged use or high doses near term); breastfeeding (oxycodone); severe bleeding disorders (aspirin); concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Hypersensitivity to olopatadine or any component of the formulation.
Avoid alcohol; may increase risk of liver damage (not applicable) and gastric bleeding. Avoid high-tyramine foods (e.g., aged cheeses, cured meats) if taking MAOIs (unlikely but caution). Take with food to minimize GI irritation.
No known food interactions. No dietary restrictions required.
Pregnancy Category D (oxycodone) and Category D (aspirin) prior to 2015 reclassification; current FDA labeling advises avoidance in pregnancy. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; oxycodone may cause neural tube defects. Second trimester: Aspirin may impair fetal renal function; oxycodone risk persists. Third trimester: Aspirin increases risk of premature closure of ductus arteriosus, oligohydramnios, and periventricular hemorrhage; oxycodone may cause neonatal withdrawal syndrome. Chronic use may lead to neonatal abstinence syndrome.
Pregnancy Category C. In animal studies, olopatadine (0.4 mg/kg/day SC) produced no teratogenic effects but caused reduced fetal weight and delayed ossification at maternally toxic doses. No adequate human studies exist. Risk cannot be ruled out; use only if benefit outweighs potential fetal risk.
Oxycodone: M/P ratio approximately 0.5; low levels in milk (0.3-6.9% of maternal weight-adjusted dose), but risk of neonatal sedation and withdrawal. Aspirin: Excreted in milk; M/P ratio ~0.03-0.1; risk of Reye's syndrome with high doses. Both drugs generally contraindicated during breastfeeding due to potential adverse effects in infants.
Olopatadine is excreted in rat milk at concentrations ~2.4 times higher than maternal plasma. No human data on M/P ratio. Caution advised; consider risk-benefit and monitor infant for anticholinergic effects.
Oxycodone: Increased clearance and volume of distribution in pregnancy may require higher doses for analgesia; dose adjustment should be individualized. Aspirin: No pharmacokinetic adjustments recommended; however, due to teratogenicity and fetal risks, use is contraindicated in pregnancy, especially during third trimester. Half-strength formulation not specifically studied; dosage should be based on oxycodone component (typically 2.25 mg) and aspirin component (325 mg) with caution.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended based on available data. Use at lowest effective dose and shortest duration.
Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid in patients with severe asthma or COPD. Assess renal function before use, as aspirin can worsen renal impairment. The half-strength formulation contains 325 mg aspirin and 2.25 mg oxycodone HCl per tablet.
Pataday Once Daily Relief contains olopatadine 0.2%, a mast cell stabilizer and antihistamine. For optimal efficacy, instruct patients to administer one drop in each affected eye once daily. Shake bottle before use. Wait at least 5 minutes before inserting contact lenses due to preservative (benzalkonium chloride). Monitor for transient burning or stinging upon instillation. Not for injection. Patients using additional ophthalmic products should separate by 5 minutes.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; risk of liver damage with acetaminophen-containing products (not applicable here), but aspirin can cause gastrointestinal bleeding.,Avoid alcohol while taking this medication.,Do not crush or chew extended-release tablets (this formulation is immediate-release; advise to swallow whole).,May cause drowsiness or dizziness; avoid driving until you know how the medication affects you.,Seek medical help if you experience signs of allergic reaction (rash, difficulty breathing) or signs of bleeding (black stools, vomiting blood).
Do not touch dropper tip to any surface to avoid contamination.,Remove contact lenses before use; wait 10 minutes before reinserting.,May cause temporary blurred vision; avoid driving until vision clears.,If you miss a dose, use it as soon as remembered, but skip if near next dose.,Keep bottle tightly closed when not in use; store at room temperature.
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCODONE AND ASPIRIN (HALF-STRENGTH) vs PATADAY ONCE DAILY RELIEF, answered by our medical review team.
OXYCODONE AND ASPIRIN (HALF-STRENGTH) is a Opioid Agonist that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, resulting in analgesia through supraspinal and spinal pathways. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin synthesis and providing anti-inflammatory and analgesic effects.. PATADAY ONCE DAILY RELIEF is a Ophthalmic Antiallergic Agent that works by Olopatadine is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits release of histamine and other mediators from mast cells, reducing allergic conjunctivitis symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCODONE AND ASPIRIN (HALF-STRENGTH) and PATADAY ONCE DAILY RELIEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCODONE AND ASPIRIN (HALF-STRENGTH) is: Adults: One to two tablets (325 mg aspirin/2.5 mg oxycodone per tablet) orally every 6 hours as needed for pain. Maximum dose: 12 tablets per day.. The standard adult dose of PATADAY ONCE DAILY RELIEF is: 1 drop in each affected eye once daily. The ophthalmic solution is 0.2% (olopatadine hydrochloride).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCODONE AND ASPIRIN (HALF-STRENGTH) and PATADAY ONCE DAILY RELIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCODONE AND ASPIRIN (HALF-STRENGTH) is classified as Category D/X. Pregnancy Category D (oxycodone) and Category D (aspirin) prior to 2015 reclassification; current FDA labeling advises avoidance in pregnancy. First trimester: Aspirin associated w. PATADAY ONCE DAILY RELIEF is classified as Category C. Pregnancy Category C. In animal studies, olopatadine (0.4 mg/kg/day SC) produced no teratogenic effects but caused reduced fetal weight and delayed ossification at maternally toxic. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.